Human melanoma antigens recognized by T lymphocytes

Yutaka Kawakami, Paul F. Robbins, Steven A. Rosenberg

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Human melanoma antigens and their epitopes recognized by T cells have been identified using a variety of methods. These antigens are classified as 1) melanocyte specific melanosomal proteins (MART-1, gp100, tyrosinase and TRP-1), 2) proteins expressed in testis and a variety of cancers (MAGE-1, MAGE-3, BAGE and GAGE), 3) tumor specific mutated proteins (β-catenin, MUM-1 and CDK4), and 4) others (p15). Some of the HLA-A2 binding non-mutated melanoma epitopes contained non-dominant anchor amino acids and have relatively low HLA-A2 binding affinity, suggesting that these epitopes were likely to be subdominant or cryptic self determinants. The significant correlation observed between vitiligo development and IL2 based immunotherapy suggested that autoreactive T cells specific for these self peptides were involved in melanoma regression in vivo. In addition, since adoptive transfer into patients of CTL recognizing these epitopes resulted in tumor regression, these epitopes may be tumor rejection antigens. Melanoma reactive CTL were efficiently induced from PBL of patients by in vitro stimulation wilh PBMC pulsed with these melanoma epitopes and may be useful in adoptive transfer protocols for the treatment of patients with metastatic melanoma. An immunization trial using the MART-1 and gp100 peptides in conjunction with incomplete Freund's adjuvant is in progress. These identified antigens may be useful for the development of new immunotherapies for the treatment of melanoma patients as well as for understanding the mechanisms of anti-tumor immune responses and autoimmune disorders against melanocytes.

Original languageEnglish
Pages (from-to)100-108
Number of pages9
JournalKeio Journal of Medicine
Volume45
Issue number2
Publication statusPublished - 1996 Jun
Externally publishedYes

Fingerprint

Melanoma-Specific Antigens
Melanoma
Epitopes
T-Lymphocytes
HLA-A2 Antigen
Adoptive Transfer
Melanocytes
Immunotherapy
Neoplasms
Antigens
Catenins
Vitiligo
Peptides
T-Lymphocyte Epitopes
Monophenol Monooxygenase
Neoplasm Antigens
Clinical Protocols
Autoimmunity
Interleukin-2
Testis

Keywords

  • cryptic self determinants
  • immunotherapy
  • MHC class I
  • T cells
  • tumor antigens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kawakami, Y., Robbins, P. F., & Rosenberg, S. A. (1996). Human melanoma antigens recognized by T lymphocytes. Keio Journal of Medicine, 45(2), 100-108.

Human melanoma antigens recognized by T lymphocytes. / Kawakami, Yutaka; Robbins, Paul F.; Rosenberg, Steven A.

In: Keio Journal of Medicine, Vol. 45, No. 2, 06.1996, p. 100-108.

Research output: Contribution to journalArticle

Kawakami, Y, Robbins, PF & Rosenberg, SA 1996, 'Human melanoma antigens recognized by T lymphocytes', Keio Journal of Medicine, vol. 45, no. 2, pp. 100-108.
Kawakami Y, Robbins PF, Rosenberg SA. Human melanoma antigens recognized by T lymphocytes. Keio Journal of Medicine. 1996 Jun;45(2):100-108.
Kawakami, Yutaka ; Robbins, Paul F. ; Rosenberg, Steven A. / Human melanoma antigens recognized by T lymphocytes. In: Keio Journal of Medicine. 1996 ; Vol. 45, No. 2. pp. 100-108.
@article{5bcc2f5a55ac4d6f8d2efcedbb753b56,
title = "Human melanoma antigens recognized by T lymphocytes",
abstract = "Human melanoma antigens and their epitopes recognized by T cells have been identified using a variety of methods. These antigens are classified as 1) melanocyte specific melanosomal proteins (MART-1, gp100, tyrosinase and TRP-1), 2) proteins expressed in testis and a variety of cancers (MAGE-1, MAGE-3, BAGE and GAGE), 3) tumor specific mutated proteins (β-catenin, MUM-1 and CDK4), and 4) others (p15). Some of the HLA-A2 binding non-mutated melanoma epitopes contained non-dominant anchor amino acids and have relatively low HLA-A2 binding affinity, suggesting that these epitopes were likely to be subdominant or cryptic self determinants. The significant correlation observed between vitiligo development and IL2 based immunotherapy suggested that autoreactive T cells specific for these self peptides were involved in melanoma regression in vivo. In addition, since adoptive transfer into patients of CTL recognizing these epitopes resulted in tumor regression, these epitopes may be tumor rejection antigens. Melanoma reactive CTL were efficiently induced from PBL of patients by in vitro stimulation wilh PBMC pulsed with these melanoma epitopes and may be useful in adoptive transfer protocols for the treatment of patients with metastatic melanoma. An immunization trial using the MART-1 and gp100 peptides in conjunction with incomplete Freund's adjuvant is in progress. These identified antigens may be useful for the development of new immunotherapies for the treatment of melanoma patients as well as for understanding the mechanisms of anti-tumor immune responses and autoimmune disorders against melanocytes.",
keywords = "cryptic self determinants, immunotherapy, MHC class I, T cells, tumor antigens",
author = "Yutaka Kawakami and Robbins, {Paul F.} and Rosenberg, {Steven A.}",
year = "1996",
month = "6",
language = "English",
volume = "45",
pages = "100--108",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "2",

}

TY - JOUR

T1 - Human melanoma antigens recognized by T lymphocytes

AU - Kawakami, Yutaka

AU - Robbins, Paul F.

AU - Rosenberg, Steven A.

PY - 1996/6

Y1 - 1996/6

N2 - Human melanoma antigens and their epitopes recognized by T cells have been identified using a variety of methods. These antigens are classified as 1) melanocyte specific melanosomal proteins (MART-1, gp100, tyrosinase and TRP-1), 2) proteins expressed in testis and a variety of cancers (MAGE-1, MAGE-3, BAGE and GAGE), 3) tumor specific mutated proteins (β-catenin, MUM-1 and CDK4), and 4) others (p15). Some of the HLA-A2 binding non-mutated melanoma epitopes contained non-dominant anchor amino acids and have relatively low HLA-A2 binding affinity, suggesting that these epitopes were likely to be subdominant or cryptic self determinants. The significant correlation observed between vitiligo development and IL2 based immunotherapy suggested that autoreactive T cells specific for these self peptides were involved in melanoma regression in vivo. In addition, since adoptive transfer into patients of CTL recognizing these epitopes resulted in tumor regression, these epitopes may be tumor rejection antigens. Melanoma reactive CTL were efficiently induced from PBL of patients by in vitro stimulation wilh PBMC pulsed with these melanoma epitopes and may be useful in adoptive transfer protocols for the treatment of patients with metastatic melanoma. An immunization trial using the MART-1 and gp100 peptides in conjunction with incomplete Freund's adjuvant is in progress. These identified antigens may be useful for the development of new immunotherapies for the treatment of melanoma patients as well as for understanding the mechanisms of anti-tumor immune responses and autoimmune disorders against melanocytes.

AB - Human melanoma antigens and their epitopes recognized by T cells have been identified using a variety of methods. These antigens are classified as 1) melanocyte specific melanosomal proteins (MART-1, gp100, tyrosinase and TRP-1), 2) proteins expressed in testis and a variety of cancers (MAGE-1, MAGE-3, BAGE and GAGE), 3) tumor specific mutated proteins (β-catenin, MUM-1 and CDK4), and 4) others (p15). Some of the HLA-A2 binding non-mutated melanoma epitopes contained non-dominant anchor amino acids and have relatively low HLA-A2 binding affinity, suggesting that these epitopes were likely to be subdominant or cryptic self determinants. The significant correlation observed between vitiligo development and IL2 based immunotherapy suggested that autoreactive T cells specific for these self peptides were involved in melanoma regression in vivo. In addition, since adoptive transfer into patients of CTL recognizing these epitopes resulted in tumor regression, these epitopes may be tumor rejection antigens. Melanoma reactive CTL were efficiently induced from PBL of patients by in vitro stimulation wilh PBMC pulsed with these melanoma epitopes and may be useful in adoptive transfer protocols for the treatment of patients with metastatic melanoma. An immunization trial using the MART-1 and gp100 peptides in conjunction with incomplete Freund's adjuvant is in progress. These identified antigens may be useful for the development of new immunotherapies for the treatment of melanoma patients as well as for understanding the mechanisms of anti-tumor immune responses and autoimmune disorders against melanocytes.

KW - cryptic self determinants

KW - immunotherapy

KW - MHC class I

KW - T cells

KW - tumor antigens

UR - http://www.scopus.com/inward/record.url?scp=0029955865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029955865&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 100

EP - 108

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 2

ER -